Evaluating prediction methods for glomerular filtration to optimise drug doses in obese and nonobese patients.
David BusseJens Markus BorghardtDavid PetroffAlice PevznerChristoph DornNahed El-NajjarWilhelm HuisingaHermann WriggePhilipp SimonCharlotte KloftPublished in: British journal of clinical pharmacology (2021)
This analysis represents a successful proof-of-concept for evaluating GFR/creatinine clearance prediction methods: Across all body mass index classes CLCRCG_ABW-Schwartz or the de-indexed MDRD were most suitable for predicting creatinine clearance/GFR also in (morbidly) obese, CKD stage <3B individuals in therapeutic use. Their application is proposed in optimising doses for vital therapies in obese patients requiring monitoring of renal function (e.g. methotrexate dosing).
Keyphrases
- obese patients
- bariatric surgery
- gastric bypass
- roux en y gastric bypass
- end stage renal disease
- body mass index
- chronic kidney disease
- weight loss
- ejection fraction
- newly diagnosed
- metabolic syndrome
- uric acid
- type diabetes
- prognostic factors
- peritoneal dialysis
- high dose
- weight gain
- endothelial cells
- low dose
- patient reported outcomes
- emergency department
- diabetic nephropathy
- electronic health record